NCT04403321View on ClinicalTrials.gov

Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

July 30, 2022

Study Completion Date

July 31, 2022

Conditions
Aplastic AnemiaDrug Effect
Interventions
DRUG

Tacrolimus

Tacrolimus will be given at 1mg bid with the target trough concentration to be 4-10 ng/mL.

DRUG

Placebo (for Tacrolimus)

placebo will be given at 1mg bid.

Trial Locations (1)

Unknown

Peking union medical college hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT04403321 - Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients | Biotech Hunter | Biotech Hunter